Home LiteratureArticle Details

PMID: 6809891 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.

Journal of neural transmission ·Vol. 54 ·No. 1-2 ·1982-00-00 ·Pages 105-10

Elsworth JD, Sandler M, Lees AJ, Ward C, Stern GM

Abstract

Although (-)-deprenyl is known to be metabolized to methamphetamine and amphetamine, two small-scale double-blind trials indicate that neither metabolite contributes to all therapeutic benefit conferred by this drug in certain patients with Parkinson's disease: the manipulation of urinary pH, which alters the rate of excretion of these metabolites, failed to change the response pattern; substitution of a metabolite mixture for active drug caused a falling off in benefit.

MeSH Terms

Amphetamine/therapeutic use,urine Double-Blind Method Drug Therapy, Combination Humans Hydrogen-Ion Concentration Levodopa/therapeutic use Methamphetamine/therapeutic use,urine Middle Aged Parkinson Disease/drug therapy,urine Phenethylamines/therapeutic use Selegiline/therapeutic use

Chemicals

Phenethylamines Selegiline Methamphetamine Levodopa Amphetamine

Authors & Affiliations

5 authors, click to expand affiliations / ORCID

Elsworth J D

Sandler M

Lees A J

Ward C

Stern G M

References (15)

15 references, click to expand

Deprenyl in Parkinson's disease.
Lancet. 1977 Oct 15;2(8042):791-5 PMID: 71602
Dopamine oxidation and its inhibition by (-)-deprenyl in man.
J Neural Transm Suppl. 1980;(16):163-72 PMID: 6776235
Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.
Psychopharmacology (Berl). 1978 Apr 14;57(1):33-8 PMID: 96466
Recent observations on the clinical pharmacology of (-)deprenyl.
J Neural Transm. 1978;43(3-4):245-51 PMID: 745017
Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation.
Psychopharmacology (Berl). 1979 Apr 11;62(2):123-8 PMID: 111274
Some puzzling pharmacological effects of monoamine oxidase inhibitors.
Adv Biochem Psychopharmacol. 1972;5:393-408 PMID: 5066229
Deprenyl is metabolized to methamphetamine and amphetamine in man.
Br J Clin Pharmacol. 1978 Dec;6(6):542-4 PMID: 728327
The possible mechanisms of action of (-)deprenyl in Parkinson's disease.
J Neural Transm. 1978;43(3-4):177-98 PMID: 745011
Urinary excretion kinetics of amphetamine in man.
J Pharm Pharmacol. 1965 Oct;17(10):628-39 PMID: 4379686
Amphetamines in the treatment of Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1975 Mar;38(3):232-7 PMID: 1097600
L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression.
Life Sci. 1980 Mar 17;26(11):877-82 PMID: 6768943
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.
J Neural Transm. 1975;36(3-4):303-26 PMID: 1172524
A method for evaluating disability in patients with Parkinson's disease.
J Nerv Ment Dis. 1961 Aug;133:143-7 PMID: 13876261
Novel (-)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action.
Biochem Pharmacol. 1978;27(13):1739-47 PMID: 708454
The inhibition of tyramine oxidation and the tyramine hypertensive response ("cheese effect") may be independent phenomena.
J Neural Transm. 1980;48(4):241-7 PMID: 6775051

Article Info

Journal

Journal of neural transmission

Abbr.

J Neural Transm

DOI

10.1007/BF01249283

Published

1982-00-00

Pages

105-10

Language

English

Region

Austria

NLM ID

0337042

Subset

External Links

PubMed source DOI: 10.1007/BF01249283

Analysis Services

The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.

Contact

WeChat Official Account